StockData
Innate Pharma SA logo

Innate Pharma SA (IPHA) stock

IPHANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as IPHYF
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 1, 2026Score 0/30
$1.49−0.10 (-6.29%)

Close on Nov 12, 2026Market cap $139.64MP/E –Yield –

Earnings

Innate Pharma's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue
–
EPS
–
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Innate Pharma's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q2 FY2026ended Jun 30, 2026Sep 17, 2026before the open–––Release
Q4 FY2025ended Dec 31, 2025Mar 26, 2026before the open–––Release
Q2 FY2025ended Jun 30, 2025Sep 17, 2025before the open–––Release
Q4 FY2024ended Dec 31, 2024Mar 27, 2025before the open–––Release
Q2 FY2024ended Jun 30, 2024Sep 12, 2024before the open–––Release
Q4 FY2023ended Dec 31, 2023Mar 21, 2024before the open–––Release
Q2 FY2023ended Jun 30, 2023Sep 14, 2023before the open–––Release
Q4 FY2022ended Dec 31, 2022Mar 23, 2023before the open–––Release
Q2 FY2022ended Jun 30, 2022Sep 15, 2022before the open–––Release
Q4 FY2021ended Dec 31, 2021Mar 24, 2022before the open–––Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Innate Pharma has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Innate Pharma puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Innate Pharma filed with the SEC as exhibits to Form 8-K or 6-K

  1. Innate Pharma to host in-person and virtual event on IPH4502 on November 18, 2026
    6-K
  2. INNATE PHARMA REPORTS THIRD QUARTER 2026 BUSINESS AND FINANCIAL UPDATE
    6-K
  3. INNATE PHARMA: PACIFIC-9 PHASE 3 TRIAL READOUT TIMING UPDATED TO H1 2027
    6-K
  4. INNATE PHARMA TO PARTICIPATE IN THE STIFEL HEALTHCARE CONFERENCE AND JEFFERIES GLOBAL HEALTHCARE CONFERENCE
    6-K
  5. INNATE PHARMA ANNOUNCES CONFERENCE CALL FOR THIRD QUARTER 2026 BUSINESS AND FINANCIAL UPDATE
    6-K
  6. INNATE PHARMA REPORTS FIRST HALF 2026 BUSINESS UPDATE AND FINANCIAL RESULTS
    6-K
  7. French société anonyme governed by a Board of Directors
    6-K
  8. INNATE AND SOBI ANNOUNCE PARTNERSHIP IS NOW EFFECTIVE FOLLOWING COMPLETION OF CLOSING CONDITIONS
    6-K
  9. Innate pharma to host conference call and webcast on september 17 for first half 2026 financial results and business update
    6-K
  10. INNATE PHARMA TO PARTICIPATE IN THE H.C. WAINWRIGHT 28TH ANNUAL GLOBAL INVESTMENT CONFERENCE
    6-K
  11. for New Ordinary Shares of
    6-K
  12. NOT FOR DISTRIBUTION IN THE UNITED STATES, AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN
    6-K
  13. NOT FOR DISTRIBUTION IN THE UNITED STATES, AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN
    6-K
  14. Innate Pharma announces conference call and webcast
    6-K
  15. INNATE PHARMA ENTERS STRATEGIC PARTNERSHIP WITH SOBI TO LICENSE LACUTAMAB IN T-CELL LYMPHOMA
    6-K

See a number that looks wrong?